Completed NA INTERVENTIONAL 2-arm NCT02342366

Characterization of the Prosocial and Prosexual Effects of GHB

Multimodal Characterization of the Prosocial and Prosexual Effects of GHB Assessing Behavior, fMRI, EEG, and Neuroendocrine Mechanisms

Sponsor: University of Freiburg

Conditions Autistic Disorder Bipolar Disorder Depressive Disorder, Major

Interventions GHB 20 mg/kg p.o. GHB 35 mg/kg p.o.

Updated 7 times since 2017 Last updated: Jul 25, 2019 Started: Feb 29, 2012 Primary completion: Nov 30, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02342366, this NA trial focuses on Autistic Disorder and Bipolar Disorder and remains completed. Sponsored by University of Freiburg, it has been updated 7 times since 2012, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Aug 2019 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Aug 2019 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Freiburg
University of Regensburg
University of Salerno
University of Vienna
University of Zurich

Data source: University of Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland